Want to see IN:SASTASUNDR full AI Analyst Report?
Top Page
Sastasundar Ventures Limited
(SASTASUNDR)
Select Model
Select Model
Rating:43Neutral
Price Target:
₹273.00
▼(-10.24% Downside)
Action:Reiterated
Date:10/01/26
Overall score is held down primarily by weak financial quality (persistent operating losses and mostly negative operating/free cash flow), with additional pressure from bearish technicals (price below key moving averages and negative MACD). A low-leverage balance sheet and recent revenue rebound provide some support, but the negative P/E and lack of dividend data limit valuation comfort.
Positive Factors
Revenue rebound and growth
The strong 2026 revenue rebound indicates that demand has remained resilient despite the prior-year decline. If sustained, renewed top-line expansion can improve operating leverage, support broader customer reach, and provide a foundation for rebuilding profitability over the next several quarters.
Negative Factors
Persistent operating losses
Persistent operating losses show that the core business has not yet demonstrated dependable economic profitability. Without a sustained improvement in operating earnings, revenue growth may not translate into durable shareholder returns and the company may remain exposed to continued financial pressure.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue rebound and growth
The strong 2026 revenue rebound indicates that demand has remained resilient despite the prior-year decline. If sustained, renewed top-line expansion can improve operating leverage, support broader customer reach, and provide a foundation for rebuilding profitability over the next several quarters.
Read all positive factors
Sastasundar Ventures Limited (SASTASUNDR) vs. iShares MSCI India ETF (INDA)
Market Cap
₹8.71B
Dividend Yield3.66%
Average Volume (3M)595.00
Price to Earnings (P/E)―
Beta (1Y)0.74
Revenue Growth32.15%
EPS Growth79.55%
CountryIN
Employees941
SectorGeneral
Sector StrengthN/A
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-6.34
Shares Outstanding31,810,500
10 Day Avg. Volume1,267
30 Day Avg. Volume595
Financial Highlights & Ratios
PEG Ratio-6.86
Price to Book (P/B)1.27
Price to Sales (P/S)0.62
P/FCF Ratio-10.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-17.6
Revenue Forecast (FY)₹33.40B
Sastasundar Ventures Limited Business Overview & Revenue Model
Company Description
Established in 1989 and headquartered in Kolkata, India, Sastasundar Ventures Limited manages a comprehensive digital healthcare ecosystem across the country. In addition to its core healthcare activities, the company provides a variety of financi...
How the Company Makes Money
Publicly verifiable, company-specific details on Sastasundar Ventures Limited’s current revenue model, key revenue streams, unit economics, and material partnerships are null. In general terms tied to its positioning around pharmacy/healthcare com...
Sastasundar Ventures Limited Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
72
Positive
Cash Flow
27
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Jun 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.60B | 13.08B | 10.90B | 13.56B | 10.38B | 6.30B |
| Gross Profit | 440.31M | 86.81M | 721.21M | 1.20B | 711.54M | 445.35M |
| EBITDA | -585.19M | -637.31M | -1.87B | -203.51M | -1.13B | 11.22B |
| Net Income | -201.95M | 11.76M | -911.67M | 88.83M | -722.11M | 6.27B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 9.36B | 9.74B | 11.50B | 12.06B | 12.78B |
| Cash, Cash Equivalents and Short-Term Investments | 302.16M | 302.16M | 124.44M | 3.95B | 2.08B | 2.12B |
| Total Debt | 0.00 | 256.56M | 11.88M | 38.83M | 93.25M | 18.53M |
| Total Liabilities | -7.65B | 1.70B | 1.10B | 1.50B | 2.12B | 1.84B |
| Stockholders Equity | 7.65B | 6.41B | 6.70B | 7.62B | 7.53B | 8.27B |
Cash Flow | ||||||
| Free Cash Flow | -326.00M | -763.79M | -276.65M | 239.34M | -1.31B | -2.12B |
| Operating Cash Flow | -271.35M | -614.47M | -173.09M | 381.65M | -1.12B | -2.07B |
| Investing Cash Flow | 406.47M | 1.58B | -11.34M | -339.27M | 1.33B | 2.20B |
| Financing Cash Flow | -19.52M | -789.64M | -4.43M | -23.52M | -18.33M | -114.22M |
Sastasundar Ventures Limited Technical Analysis
Negative
304.15
Price Trends
300.03
Negative
304.18
Negative
296.71
Negative
Market Momentum
-5.64
Positive
37.88
Neutral
17.18
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SASTASUNDR, the sentiment is Negative. The current price of 304.15 is above the 20-day moving average (MA) of 293.52, above the 50-day MA of 300.03, and above the 200-day MA of 296.71, indicating a bearish trend. The MACD of -5.64 indicates Positive momentum. The RSI at 37.88 is Neutral, neither overbought nor oversold. The STOCH value of 17.18 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:SASTASUNDR.
Sastasundar Ventures Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ₹11.66B | 11.78 | ― | 0.32% | 10.20% | 11.70% | |
71 Outperform | ₹69.82B | 21.51 | ― | 4.07% | -8.88% | -10.68% | |
56 Neutral | ₹13.64B | 51.97 | ― | 1.12% | 11.96% | -28.48% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | ₹10.51B | 26.01 | ― | 0.45% | -12.75% | ― | |
52 Neutral | ₹78.61B | 36.72 | ― | ― | 16.79% | 17.67% | |
43 Neutral | ₹8.71B | -44.57 | ― | 3.66% | 32.15% | 79.55% |
* General Sector Average
IN:SASTASUNDR
Sastasundar Ventures Limited
271.55
-38.00
-12.28%
IN:KOPRAN
Kopran Limited
268.75
93.87
53.67%
IN:LINCOLN
Lincoln Pharmaceuticals Ltd
568.55
42.39
8.06%
IN:MEDPLUS
MedPlus Health Services Ltd.
643.95
-114.45
-15.09%
IN:SANOFI
Sanofi India Limited
3,025.30
-1,627.26
-34.98%
IN:THEMISMED
Themis Medicare Limited
112.20
-18.12
-13.90%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.